靶向有氧糖酵解途径治疗卵巢癌的研究进展
Research Progress in Targeted Aerobic Glycolysis Pathway for the Treatment of Ovarian Cancer
DOI: 10.12677/HJBM.2023.134041, PDF,   
作者: 杨思齐, 张 燕*：佳木斯大学附属第一医院妇产科，黑龙江 佳木斯；杨荣舜：佳木斯大学附属第一医院泌尿外科，黑龙江 佳木斯
关键词: 卵巢癌；有氧糖酵解；靶向阻遏；治疗策略；Ovarian Cancer； Aerobic Glycolysis； Targeted Repression； Treatment Strategies
摘要: 卵巢癌是是妇产科死亡较高的恶性肿瘤之一，其疾病多数快速进展及隐匿，给患者和医生们带来了巨大的困扰；有氧糖酵解是指肿瘤即使在氧气充足的情况下，依然偏好于糖酵解进行物质代谢产生能量，为肿瘤快速生长及繁殖提供条件；因此，如果能对肿瘤的这种代谢重编程进行靶向阻遏，就有可能阻断肿瘤细胞生长复制，并提高药物对肿瘤的敏感性，故靶向阻断有氧糖酵解可能是一种有前景的治疗策略，本文将针对卵巢癌糖酵解途径治疗的研究进展进行概述。
Abstract: Ovarian cancer is one of the malignant tumors with a high mortality rate in obstetrics and gynecology, and most of its diseases are rapidly progressing and hidden, causing great distress to patients and doctors; aerobic glycolysis refers to the preference of tumors for glycolysis to metabolize substances and generate energy even when oxygen is sufficient, providing conditions for rapid growth and reproduction of tumors; therefore, if targeted inhibition of the metabolic reprogramming of tumors can be carried out, it is possible to block the growth and replication of tumor cells and improve the sensitivity of drugs to tumors. Therefore, targeted blockade of aerobic glycolysis may be a promising treatment strategy. This article will provide an overview of the research progress in the treatment of ovarian cancer through the glycolysis pathway.
文章引用：杨思齐, 杨荣舜, 张燕. 靶向有氧糖酵解途径治疗卵巢癌的研究进展[J]. 生物医学, 2023, 13(4): 354-358. https://doi.org/10.12677/HJBM.2023.134041

参考文献

[1] Stewart, C., Ralyea, C. and Lockwood, S. (2019) Ovarian Cancer: An Integrated Review. Seminars in Oncology Nursing, 35, 151-156. [Google Scholar] [CrossRef] [PubMed]
[2] Ree, I.A., White, V.A., Indave, B.I. and Lokuhetty, D. (2020) Revising the WHO Classification: Female Genital Tract Tumours. Histopathology, 76, 151-156. [Google Scholar] [CrossRef] [PubMed]
[3] Vergote, I., González-Martín, A., Ray-Coquard, I., Harter, P., Colombo, N., Pujol, P., et al. (2022) European Experts Consensus: BRCA/Homologous Recombination Deficiency Testing in First-Line Ovarian Cancer. Annals of Oncology, 33, 276-287. [Google Scholar] [CrossRef] [PubMed]
[4] Zhang, C. and Liu, N. (2022) Noncoding RNAs in the Glycolysis of Ovarian Cancer. Frontiers in Pharmacology, 13, Article ID: 855488. [Google Scholar] [CrossRef] [PubMed]
[5] Warburg, O. (1956) On the Origin of Cancer Cells. Science, 123, 309-314. [Google Scholar] [CrossRef] [PubMed]
[6] Han, C.Y., Patten, D.A., Kim, S.I., Lim, J.J., Chan, D.W., et al. (2021) Nuclear HKII-P-p53 (Ser15) Interaction Is a Prognostic Biomarker for Chemoresponsiveness and Glycolytic Regulation in Epithelial Ovarian Cancer. Cancers (Basel), 13, Article No. 3399. [Google Scholar] [CrossRef] [PubMed]
[7] Kenny, H.A., Hart, P.C., Kordylewicz, K., Lal, M., Shen, M., Kara, B., et al. (2021) The Natural Product β-Escin Targets Cancer and Stromal Cells of the Tumor Microenvironment to Inhibit Ovarian Cancer Metastasis. Cancers (Basel), 13, Article No. 3931. [Google Scholar] [CrossRef] [PubMed]
[8] 李莉, 侯志敏. 卵巢癌组织中miR-125B-5p通过调控己糖激酶-2降低肿瘤能量代谢和抑制肿瘤细胞增殖[J]. 癌症, 2021, 40(9): 394-403.
[9] 王慧, 王静, 闫冬娟, 等. 二氢黄腐酚通过调控HK2表达对人卵巢癌顺铂耐药细胞株SKOV3/DDP的耐药性影响[J]. 医学研究生学报, 2022, 35(8): 806-812.
[10] 林莉香, 云红叶, 黄守国. 二甲双胍通过己糖激酶2调节糖酵解途径抑制卵巢癌细胞增殖和迁移[J]. 中国老年学杂志, 2022, 42(9): 2242-2245.
[11] Schab, A.M., Greenwade, M.M., Stock, E., Lomonosova, E., Cho, K., Grither, W.R., et al. (2023) Stromal DDR2 Promotes Ovarian Cancer Metastasis through Regulation of Metabolism and Secretion of Extracellular Matrix Proteins. Molecular Cancer Research, OF1-OF15. [Google Scholar] [CrossRef] 
[12] Vidoni, C., Ferraresi, A., Vallino, L., Salwa, A., Ha, J.H., Seca, C., et al. (2023) Glycolysis Inhibition of Autophagy Drives Malignancy in Ovarian Cancer: Exacerbation by IL-6 and Attenuation by Resveratrol. International Journal of Molecular Sciences, 24, Article No. 1723. [Google Scholar] [CrossRef] [PubMed]
[13] Chun, J. (2023) Isoalantolactone Suppresses Glycolysis and Resensitizes Cisplatin-Based Chemotherapy in Cisplatin-Resistant Ovarian Cancer Cells. International Journal of Molecular Sciences, 24, Article No. 12397. [Google Scholar] [CrossRef] [PubMed]
[14] Taylor, C., Mannion, D., Miranda, F., Karaminejadranjbar, M., Herrero-Gonzalez, S., Hellner, K., et al. (2017) Loss of PFKFB4 Induces Cell Death in Mitotically Arrested Ovarian Cancer Cells. Oncotarget, 8, 17960-17980. [Google Scholar] [CrossRef] [PubMed]
[15] Mondal, S., Roy, D., Sarkar Bhattacharya, S., Jin, L., Jung, D., Zhang, S., et al. (2019) Therapeutic Targeting of PFKFB3 with a Novel Glycolytic Inhibitor PFK158 Promotes Lipophagy and Chemosensitivity in Gynecologic Cancers. International Journal of Cancer, 144, 178-189. [Google Scholar] [CrossRef] [PubMed]
[16] Yang, H., Shu, Z., Jiang, Y., Mao, W., Pang, L., Redwood, A., et al. (2019) 6-Phosphofructo-2-Kinase/Fructose- 2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers. Clinical Cancer Research, 25, 5702-5716. [Google Scholar] [CrossRef] 
[17] Boscaro, C., Baggio, C., Carotti, M., Sandonà, D., Trevisi, L., Cignarella, A. and Bolego, C. (2022) Targeting of PFKFB3 with miR-206 but Not mir-26b Inhibits Ovarian Cancer Cell Proliferation and Migration Involving FAK Downregulation. FASEB Journal, 36, e22140. [Google Scholar] [CrossRef] 
[18] Jia, Y.S., Yang, L., Zhu, Y.Q. and Ma, C.B. (2023) Beta-Catenin Knockdown Impairs the Viability of Ovarian Cancer Cells by Modulating YAP-Dependent Glycolysis. American Journal of Translational Research, 15, 982-994.
[19] Tae, I.H., Son, J.Y., Lee, S.H., Ahn, M.Y., Yoon, K., Yoon, S., Moon, H.R. and Kim, H.S. (2020) A New SIRT1 Inhibitor, MHY2245, Induces Autophagy and Inhibits Energy Metabolism via PKM2/mTOR Pathway in Human Ovarian Cancer Cells. International Journal of Biological Sciences, 16, 1901-1916. [Google Scholar] [CrossRef] [PubMed]
[20] Park, J.H., Kundu, A., Lee, S.H., Jiang, C., Lee, S.H., Kim, Y.S., Kyung, S.Y., Park, S.H. and Kim, H.S. (2021) Specific Pyruvate Kinase M2 Inhibitor, Compound 3K, Induces Autophagic Cell Death through Disruption of the Glycolysis Pathway in Ovarian Cancer Cells. International Journal of Biological Sciences, 17, 1895-1908. [Google Scholar] [CrossRef] [PubMed]
[21] Sun, T., Liu, Z., Bi, F. and Yang, Q. (2021) Deubiquitinase PSMD14 Promotes Ovarian Cancer Progression by Decreasing Enzymatic Activity of PKM2. Molecular Oncology, 15, 3639-3658. [Google Scholar] [CrossRef] [PubMed]
[22] Dou, L., Lu, E., Tian, D., Li, F., Deng, L. and Zhang, Y. (2023) Adrenomedullin Induces Cisplatin Chemoresistance in Ovarian Cancer through Reprogramming of Glucose Metabolism. Journal of Translational Internal Medicine, 11, 169-177.
[23] Zhou, S., Li, D., Xiao, D., Wu, T., Hu, X., Zhang, Y., et al. (2022) Inhibition of PKM2 Enhances Sensitivity of Olaparib to Ovarian Cancer Cells and Induces DNA Damage. International Journal of Biological Sciences, 18, 1555-1568. [Google Scholar] [CrossRef] [PubMed]

为你推荐